Lion Corporation (JP:4912)
:4912
Top Page
Lion
(4912)
Select Model
Select Model
Rating:76Outperform
Price Target:
¥1,803.00
▲(7.90% Upside)
Action:ReiteratedDate:02/18/26
The score is driven primarily by solid financial health and improving profitability, alongside strong technical momentum with the stock trading above key moving averages. Valuation is acceptable but not especially cheap, and the dividend yield is modest, slightly tempering the overall score.
Positive Factors
Diversified brand & distribution
Lion's broad product mix across oral care, personal care, household goods and pharmaceuticals, combined with strong brands, R&D and an extensive distribution footprint in Japan and Asia, supports resilient demand, cross-selling and steady revenue generation across cycles.
Negative Factors
Margin compression
Net margin contraction from ~8.4% in 2020 to ~5.1% in 2024 signals structural pressure from cost inflation, adverse mix or pricing limits. Persistent margin erosion would cap profit upside and require sustained efficiency gains to restore prior profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified brand & distribution
Lion's broad product mix across oral care, personal care, household goods and pharmaceuticals, combined with strong brands, R&D and an extensive distribution footprint in Japan and Asia, supports resilient demand, cross-selling and steady revenue generation across cycles.
Read all positive factors
Lion (4912) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥433.02B
Dividend Yield1.73%
Average Volume (3M)1.11M
Price to Earnings (P/E)16.5
Beta (1Y)0.38
Revenue Growth2.18%
EPS Growth60.81%
CountryJP
Employees7,654
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)24.49
Shares Outstanding279,782,750
10 Day Avg. Volume1,063,460
30 Day Avg. Volume1,106,010
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)1.41
Price to Sales (P/S)1.08
P/FCF Ratio20.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,092.86Price Target Upside25.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)94.15
Revenue Forecast (FY)¥431.73B
Lion Business Overview & Revenue Model
Company Description
Lion Corporation manufactures and sells consumer and industrial products in Japan and internationally. It operates through three segments: Consumer Products Business, Industrial Products Business, and Overseas Business. The company offers dental a...
How the Company Makes Money
Lion Corporation generates revenue primarily through the sale of its consumer products, including oral care items, such as toothpaste and toothbrushes; beauty and personal care products; and household cleaning agents, including detergents and fabr...
Lion Earnings Call Summary
Earnings Call Date:Nov 07, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted an increase in net sales and profits, driven by effective price revisions and structural reforms. However, challenges such as impairment losses, a decline in domestic sales, and a slowdown in certain overseas markets were also noted. The partnership with Japan Activation Capital is a strategic move to bolster future growth.Positive Updates
Increased Net Sales and Profits
Net sales were JPY 301.1 billion, up 1.7% year-on-year. Core operating income was JPY 18.6 billion, an increase of JPY 6 billion year-on-year.
Negative Updates
Impairment Loss on Domestic Facilities
Impairment loss of approximately JPY 6.2 billion due to streamlining of domestic home care production facilities.
Read all updates
Q3-2024 Updates
Positive
Negative
Increased Net Sales and Profits
Net sales were JPY 301.1 billion, up 1.7% year-on-year. Core operating income was JPY 18.6 billion, an increase of JPY 6 billion year-on-year.
Read all positive updates
Company Guidance
In the earnings call for Q3 2024, Lion Corporation reported a 1.7% increase in net sales to JPY 301.1 billion, with a core operating income rise of JPY 6 billion year-on-year, reaching JPY 18.6 billion. The EBITDA was JPY 32.5 billion, up by JPY 6.4 billion, with a margin increase of 2 percentage points to 10.8%. Despite an impairment loss of JPY 6.2 billion due to domestic production facility streamlining, the company maintained its full-year forecast, attributing the resilient performance to price revisions and cost reductions, specifically mentioning a JPY 2.8 billion price revision impact and a total cost reduction of JPY 2.2 billion. The consumer product sales in Japan fell by 4.3%, whereas overseas sales showed sustained double-digit growth. The company plans further asset sales in Q4 to support ongoing structural reforms, aiming for a total shareholder return ratio of 91.9% with a dividend set at JPY 27 per share.Lion Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
83
Very Positive
Cash Flow
68
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 422.09B | 412.94B | 402.77B | 389.87B | 366.23B |
| Gross Profit | 193.92B | 188.78B | 180.60B | 174.61B | 179.10B |
| EBITDA | 51.89B | 46.76B | 39.63B | 40.88B | 44.93B |
| Net Income | 27.59B | 21.20B | 14.63B | 21.94B | 23.76B |
Balance Sheet | |||||
| Total Assets | 528.60B | 497.17B | 486.36B | 469.28B | 428.02B |
| Cash, Cash Equivalents and Short-Term Investments | 88.09B | 102.24B | 85.53B | 101.08B | 97.25B |
| Total Debt | 54.44B | 29.74B | 30.34B | 32.17B | 8.37B |
| Total Liabilities | 180.17B | 181.47B | 188.23B | 190.11B | 163.01B |
| Stockholders Equity | 322.73B | 293.72B | 280.32B | 264.25B | 251.57B |
Cash Flow | |||||
| Free Cash Flow | 22.57B | 25.60B | 6.34B | 23.47B | -17.99B |
| Operating Cash Flow | 40.65B | 43.66B | 30.07B | 41.96B | 19.30B |
| Investing Cash Flow | -43.37B | -7.19B | -34.37B | -19.54B | -34.18B |
| Financing Cash Flow | -12.50B | -21.67B | -12.19B | -19.82B | -10.22B |
Lion Technical Analysis
Negative
1671.00
Price Trends
1721.66
Negative
1667.19
Negative
1597.57
Negative
Market Momentum
-27.88
Positive
31.97
Neutral
0.57
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4912, the sentiment is Negative. The current price of 1671 is below the 20-day moving average (MA) of 1737.88, below the 50-day MA of 1721.66, and above the 200-day MA of 1597.57, indicating a bearish trend. The MACD of -27.88 indicates Positive momentum. The RSI at 31.97 is Neutral, neither overbought nor oversold. The STOCH value of 0.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4912.
Lion Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥1.66T | 23.99 | 10.79% | 3.47% | -1.56% | -1.15% | |
76 Outperform | ¥433.02B | 16.53 | 9.09% | 1.73% | 2.18% | 60.81% | |
71 Outperform | ¥544.30B | 13.97 | 12.66% | 1.53% | 18.35% | 31.87% | |
70 Outperform | ¥2.72T | 24.05 | 11.50% | 2.41% | 4.62% | 47.68% | |
69 Neutral | ¥331.52B | 19.79 | 2.72% | 2.61% | 1.37% | -5.60% | |
65 Neutral | ¥415.98B | 110.37 | 5.37% | 1.95% | -3.33% | 13.76% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
* Consumer Defensive Sector Average
JP:4912
Lion
1,609.00
-130.13
-7.48%
JP:4452
Kao
6,022.00
-379.23
-5.92%
JP:4967
Kobayashi Pharmaceutical Co
5,693.00
12.25
0.22%
JP:4922
Kose
5,833.00
-501.54
-7.92%
JP:4527
Rohto Pharmaceutical Co
2,373.00
138.70
6.21%
JP:8113
Unicharm
924.30
-238.79
-20.53%
Lion Corporate Events
Lion to Book ¥15.9 Billion Extraordinary Gain From Sale of Chemical Subsidiaries
Feb 16, 2026
Lion Corporation will record an estimated ¥15,953 million in extraordinary income on a non-consolidated basis from the transfer of all shares in two consolidated subsidiaries in its chemical products business. The gain arises from the sale of...
Lion to Divest Specialty Chemicals Units to Advantage Partners-Backed AP88
Feb 12, 2026
Lion Corporation has decided to transfer all shares of its consolidated subsidiary Lion Specialty Chemicals Co., Ltd. and that company’s Indonesian subsidiary PT. IPPOSHA INDONESIA to AP88 Co., Ltd., a vehicle backed by a fund serviced by Ad...
Lion boosts profit and dividends as 2025 earnings strengthen balance sheet
Feb 12, 2026
Lion Corporation reported a 2.2% rise in net sales to ¥422.1 billion for 2025, while operating profit jumped 28.1% and profit attributable to owners of the parent climbed 30.1%, reflecting improved margins and solid core operating income grow...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.